Degarelix Acetate is a synthetic GnRH receptor antagonist that immediately suppresses LH and FSH without an initial testosterone surge, used in advanced prostate cancer. Simson Pharma's Degarelix Acetate reference standard and impurities support QC for this injectable peptide-based hormonal therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Degarelix acetate Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.